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Introduction
Perfluoroalkyl acids (PFAAs) constitute a class 
of synthetic chemicals whose water and oil 
repellency and surfactant properties have useful 
applications in a wide range of industrial and 
commercial products (Lindstrom et al. 2011). 
Some PFAAs are persistent and ubiquitous in 
the environment, and can be found in higher 
concentrations at higher levels in the food 
chain (Stockholm Convention 2014). Human 
exposure to PFAAs is common (Joensen et al. 
2013; Kato et al. 2011). Detectable concentra-
tions of some PFAAs in cord blood (Apelberg 
et al. 2007) and amniotic fluid from pregnant 
women (Stein et al. 2012) suggest human 
fetal exposure.
Effects of endocrine disruptors on repro-
duction may originate during the fetal stage 
(Crain et al. 2008), yet current knowledge 
on whether prenatal exposures to PFAAs can 
have an impact on human reproduction is 
limited to few studies. A longitudinal study of 
young adult females investigated associations 
of prenatal exposure to perfluoro octanoic 
acid (PFOA) and perfluorooctane sulfonic 
acid (PFOS) on menstrual characteristics, 
reproductive hormone levels, and number of 
follicles (Kristensen et al. 2013). In this study 
prenatal exposure to perfluoro octanoic acid 
(PFOA) was associated with delayed menarche 
attainment but not with other markers of 
reproductive function, whereas prenatal 
exposure to PFOS was not associated with any 
of the study outcomes (Kristensen et al. 2013). 
A nested case–control study conducted by our 
group explored the role of prenatal exposure to 
PFAAs on timing of menarche (Christensen 
et al. 2011). We did not find evidence of an 
association between prenatal exposure to the 
PFAAs tested and earlier menarche attainment. 
Last, a study of young adults explored whether 
prenatal PFOA or PFOS exposure was associ-
ated with semen quality, testicular volume, and 
reproductive hormone levels. Inverse associa-
tions of sperm concentration and total sperm 
count and positive associations of luteinizing 
and follicle-stimulating hormone with prenatal 
PFOA exposure were observed (Vested et al. 
2013). To our knowledge, studies exploring 
effects of prenatal exposures to PFAAs on 
hormone concentrations in experimental 
animals have not been conducted.
Reproductive effects of many endo-
crine disruptors are thought to be mediated 
mainly by agonistic or antagonistic nuclear 
sex hormone receptor processes (Crain et al. 
2008). It would appear, however, that PFAAs 
could impair human reproduction through 
other pathways. For instance, some PFAAs 
are known to increase mouse and human 
peroxisome proliferator–activated receptor 
alpha (PPARα) subtype activity (Takacs 
and Abbott 2007; Wolf et al. 2008), which 
influences lipid metabolism. Positive associa-
tions between exposure to PFAAs and lipids 
have been noted in adolescents and pregnant 
women from population-based cross-sectional 
epidemiologic reports (Geiger et al. 2014; 
Starling et al. 2014). Because cholesterol 
is the substrate from which reproductive 
hormones are synthesized (Burger 2002), 
exposure to PFAAs have the potential to 
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Background: Exposure to perfluorooctane sulfonic acid (PFOS) or to perfluorooctanoic acid 
(PFOA) increases mouse and human peroxisome proliferator–activated receptor alpha (PPARα) 
subtype activity, which influences lipid metabolism. Because cholesterol is the substrate from which 
testosterone is synthesized, exposure to these substances has the potential to alter testosterone 
concentrations.
oBjectives: We explored associations of total testosterone and sex hormone–binding globulin 
(SHBG) concentrations at age 15 years with prenatal exposures to PFOS, PFOA, perfluorohexane 
sulfonic acid (PFHxS), and perfluoronanoic acid (PFNA) in females.
Methods: Prenatal concentrations of the perfluoroalkyl acids (PFAAs) were measured in serum 
collected from pregnant mothers at enrollment (1991–1992) in the Avon Longitudinal Study of 
Parents and Children (ALSPAC). The median gestational age when the maternal blood sample was 
obtained was 16 weeks (interquartile range, 11–28 weeks). Total testosterone and SHBG concen-
trations were measured in serum obtained from their daughters at 15 years of age. Associations 
between prenatal PFAAs concentrations and reproductive outcomes were estimated using linear 
regression models (n = 72).
results: Adjusted total testosterone concentrations were on average 0.18-nmol/L (95% CI: 
0.01, 0.35) higher in daughters with prenatal PFOS in the upper concentration tertile compared 
with daughters with prenatal PFOS in the lower tertile. Adjusted total testosterone concentrations 
were also higher in daughters with prenatal concentrations of PFOA (β = 0.24; 95% CI: 0.05, 0.43) 
and PFHxS (β = 0.18; 95% CI: 0.00, 0.35) in the upper tertile compared with daughters with 
concentrations in the lower tertile. We did not find evidence of associations between PFNA and 
total testosterone or between any of the PFAAs and SHBG.
conclusions: Our findings were based on a small study sample and should be interpreted with 
caution. However, they suggest that prenatal exposure to some PFAAs may alter testosterone 
concentrations in females.
citation: Maisonet M, Calafat AM, Marcus M, Jaakkola JJ, Lashen H. 2015. Prenatal 
exposure to perfluoroalkyl acids and serum testosterone concentrations at 15 years of age in 
female ALSPAC study participants. Environ Health Perspect 123:1325–1330; http://dx.doi.
org/10.1289/ehp.1408847
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alter concentrations of bioavailable circu-
lating hormones. Alternatively, there is some 
evidence that endocrine disruptors, including 
PFOS, bind to sex hormone–binding globulin 
(SHBG) (Jones et al. 2003), and displace-
ment of reproductive hormones from SHBG 
binding sites could alter bioavailability of 
circulating hormones (Déchaud et al. 1999).
High serum testosterone concentrations in 
females are a main feature of polycystic ovary 
syndrome (PCOS) that is associated with 
disruption of reproductive function (Azziz 
et al. 2009) as well as long-term sequelae such 
as metabolic disorders (Apridonidze et al. 
2005) and possibly increased cardiovascular 
disease risk (Cibula et al. 2000). We report 
results of a study conducted to explore associa-
tions of prenatal exposures to PFOS, PFOA, 
perfluorohexane sulfonic acid (PFHxS), and 
perfluoronanoic acid (PFNA) with testos-
terone and SHBG serum concentrations at 
15 years of age in females enrolled in the Avon 
Longitudinal Study of Parents and Children 
(ALSPAC). This study focused on female 
participants because data on prenatal PFAAs 
exposure in males enrolled in the ALSPAC are 
not yet available for analyses.
Methods
Source population. The ALSPAC study 
enrolled pregnant women from three 
health districts of the old administrative 
county of Avon, United Kingdom, with an 
expected delivery date between April 1991 
and December 1992. A total of 14,541 
pregnant women, approximately 72% of the 
eligible source population, enrolled in the 
cohort during the 1990–1992 recruitment 
campaign. Details of recruitment methods are 
described elsewhere (Boyd et al. 2013).
Study population. We linked concen-
trations of PFAAs measured in enrolled 
pregnant women with their daughters’ serum 
concentrations of total testosterone and 
SHBG measured at 15 years of age using 
data from two separate investigations previ-
ously conducted on the ALSPAC. Maternal 
concentrations of PFAAs were measured in 
banked blood for a nested case–control study 
of prenatal exposures to PFAAs and menarche 
in daughters (Christensen et al. 2011). The 
median gestational age when maternal blood 
samples were obtained was 16 weeks [inter-
quartile range (IQR), 11–28 weeks]. Total 
testosterone and SHBG concentrations were 
measured in serum samples collected from the 
1,790 adolescent females who participated in 
the 15-years clinic visit open to all members of 
the ALSPAC cohort.
Cases in the nested case–control study 
consisted of 218 daughters who attained 
menarche at < 11.5 years and controls were a 
random sample of 230 daughters who attained 
menarche at ≥ 11.5 years of age (Christensen 
et al. 2011). We restricted the present study to 
daughters from the control sample (n = 230) 
because these are representative of the range 
of ages when menarche is most commonly 
attained. Not everyone who participated in 
the 15-years clinic visit had been a part of the 
case–control study; thus, after linkage of the 
230 controls with the 1,790 clinic partici-
pants, only 72 females had prenatal concentra-
tions of PFAAs and serum testosterone and 
SHBG concentrations at age 15 years available 
for the analyses.
Covariates. Covariates were selected 
a priori. Maternal covariates considered in the 
analyses were maternal smoking during preg-
nancy (yes, no); age at delivery (years); and 
prepregnancy body mass index (BMI; kilo-
grams per meter squared) (Ernst et al. 2012; 
Sowers et al. 2001). Maternal educational level 
was also included in the set of maternal covari-
ates as a measure of socioeconomic status 
(lowest: none/Certification of Secondary 
Education or Vocational; middle: Ordinary 
Level; highest: Advanced Level or University 
Degree). An Ordinary Level education is the 
qualification obtained at age 16 years when 
obligatory schooling ends, and an Advanced 
Level education is secondary or pre-university 
education certification. Daughters’ covariates 
considered in the analyses were serum SHBG 
concentrations at 15 years (nanomoles per 
liter), BMI at 15 years, age at menarche (< 12, 
12–13, 14 years), and time of day the blood 
sample for testosterone testing was obtained 
(Ankarberg and Norjavaara 1999; Brand 
et al. 2011). Daughters’ BMI at age 15 years 
and age at menarche were also considered as 
covariates for the analyses for SHBG. There is 
a possibility that daughter’s BMI at 15 years 
might be affected by total testosterone and 
SHBG serum concentrations at 15 years or 
that daughter’s age at menarche might be 
affected by total testosterone serum concentra-
tions. In such circumstances, use of BMI at 
15 years or of age at menarche as covariates 
would be unnecessary. Data collection instru-
ments and study variables have been described 
in detail elsewhere (ALSPAC 2014; Fraser 
et al. 2013).
Laboratory analyses. One total testos-
terone and one SHBG measure was made on 
serum samples obtained from daughters at 
age 15 years. About half of the blood samples 
were drawn between 0800 and 0900 hours 
and the other half between 1200 and 1500 
hours. Total testosterone was measured using 
Agilent triple quadrupole 6410 liquid chroma-
tography/mass spectrometry equipment with 
an electrospray ionization source operating 
in positive ion mode (Agilent Technologies, 
Wilmington, DE, USA). Multiple reaction 
monitoring was used to quantify total 
testosterone by using trideuterated testos-
terone (d3t-testosterone), with the following 
transitions: m/z 289.2-97 and 289.2-109 for 
testosterone and 292.2-97 and 292.2-109 for 
d3t-testosterone. The coefficients of varia-
tion of the method were 5.3, 1.6, and 1.2% 
for testosterone at 0.6, 6.6, and 27.7 nmol/L 
respectively. In an adult female population, 
the total testosterone reference range of 0.27–
1.56 nmol/L has been suggested for measure-
ments obtained by liquid chromatography/
mass spectrometry (Kane et al. 2007). SHBG 
was measured using a Cobas Auto Analyzer 
(Roche Diagnostic, West Sussex, UK) and 
SHBG reagent using the manufacturer’s 
 calibrators and quality control material.
PFOS, PFOA, PFHxS, and PFNA were 
measured in stored maternal sera collected 
during 1991–1992 at pregnancy. The median 
gestational age when samples were obtained 
was 15 weeks and the IQR was 10–28 weeks. 
Serum was analyzed using online phase 
extraction–high performance liquid chroma-
tography–isotope dilution tandem mass spec-
trometry as described elsewhere (Kuklenyik 
et al. 2005). Limits of detection (LOD) were 
0.2 ng/mL (PFOS), 0.1 ng/mL (PFOA, 
PFHxS), and 0.082 ng/mL (PFNA). A correc-
tion factor of 0.82 was applied to the PFNA 
concentrations to adjust for the purity of the 
analytic standards used [Centers for Disease 
Control and Prevention (CDC) 2013]. The 
precision of measurements, expressed as the 
relative standard deviation, was 8–13%, 
depending on the analyte. Prenatal concen-
trations of all PFAA analytes measured 
in the study group were above the LOD. 
Low-concentration (~ 2–9 ng/mL) and high-
concentration (~ 6–25 ng/mL) quality control 
(QC) materials prepared with pooled serum 
were analyzed with standards, reagent blanks, 
and study samples. The concentrations of the 
QCs and blanks were evaluated using standard 
statistical probability rules.
Statistical analyses. Means of study 
outcomes by tertiles of prenatal PFAAs 
concentrations exhibited equal variances (data 
not shown). The null hypothesis for homo-
geneity of variances was tested separately for 
either total testosterone or SHBG concen-
trations with each prenatal PFAA using the 
Bartlett test, and none rejected at p < 0.05.
We used generalized additive models to 
detect whether associations between prenatal 
PFAA concentrations and the study outcomes 
exhibited departures from linearity (Hastie 
and Tibshirani 1987). We fitted these models 
with a smooth term for the continuous 
PFAAs for each prenatal PFAA and daughter’s 
outcomes combination separately. All smooth 
terms were fitted with 3 degrees of freedom. 
Chi-square tests from analyses of deviance 
comparing models with and without the 
smooth exposure term were performed, and 
no statistical departures from linearity were 
apparent at a p < 0.05 level of significance.
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For analyses of prenatal continuous 
PFAAs, we estimated associations with total 
testosterone concentrations before and after 
exclusion of influential data points. We 
used studentized residuals (> 2.5 or < –2.5), 
leverage [>(2 number of predictor+2)/n], 
Cook’s distance (> 4/n), and visual observation 
of scatter plots as diagnostic tools to identify 
influential data points. After applying these 
criteria, two data points with corresponding 
values of PFOS of 66.4 and 69.2 ng/mL; 
two data points with corresponding values of 
PFOA of 13.8 and 14.6 ng/mL; three data 
points with corresponding values of PFHxS 
of 17.5, 49.8, and 54.1 ng/mL; and three data 
points with corresponding values of PFNA of 
0.98, 1.07, and 1.15 ng/mL were excluded 
from respective models. It is important to 
underscore that influential data points identi-
fied using statistical methods do exhibit values 
of PFAAs concentrations observed in the 
human populations.
We report results from three separate linear 
regression models for the associations between 
the study outcomes and each PFAA: a) unad-
justed model, b) fully adjusted, c) adjusted only 
by the covariates that were associated with the 
model’s respective PFAA at p < 0.20.
Human subject protection was assessed 
and approved by the ALSPAC Law and Ethics 
Committee and the Local Research Ethics 
Committees. Collection of pubertal data 
was also approved by the CDC Institutional 
Review Board. Human participants gave 
written informed consent before enrollment in 
the ALSPAC. Parental consent was obtained 
at the 15-years clinic visit because daughters 
were underage. Daughters could refuse any 
procedure requiring consent at any time 
during the clinic visit.
Results
PFOS showed the highest median prenatal 
concentration (19.2 ng/mL) followed by 
PFOA (3.6 ng/mL), PFHxS (1.6 ng/mL), 
and PFNA (0.5 ng/mL) (Table 1). Spearman 
correlation coefficients suggest a moderate 
level of correlation between PFAAs: r values 
ranged between 0.47 and 0.65 (plots not 
shown). Median serum concentrations of 
total testosterone and SHBG in daughters at 
15 years were 0.8 and 52.1 nmol/L, respec-
tively (Table 1). The Pearson correlation coef-
ficient between serum total testosterone and 
SHBG suggests a weak correlation (r = 0.11) 
between these two variables (plot not shown). 
The age range of the daughters in our study 
group was 15.0–15.9 years. All daughters had 
attained menarche and none used hormonal 
contraception. More than 50% of mothers 
reported having an advanced level or university 
degree education and delivering her daughter 
at ≥ 30 years of age. All of the mothers were 
of white race and had, on average, a normal 
prepregnancy weight (Table 2). Scatter 
plots for total testosterone concentrations 
in 15-year-old daughters by prenatal PFOS, 
PFOA, PFHxS, and PFNA serum concentra-
tions with unadjusted linear regression line 
(Figure 1) suggest higher total testosterone 
serum concentrations with increasing values 
of prenatal PFAAs concentrations. There is 
also a suggestion of outlying values for PFOA, 
PFOS, and PFHxS.
Given the size of the study group, 
we created two adjusted models to deter-
mine associations between the outcomes 
and each prenatal PFAA separately. One 
adjusted model, which we refer to as the 
fully adjusted model, included all covariates 
identified a priori. The other, which we refer 
to as the parsimonious model, included only 
those covariates associated with the model’s 
corresponding PFAA at p < 0.20. In the 
fully adjusted linear regression model, total 
testosterone concentrations were on average 
0.18-nmol/L [95% confidence interval 
(CI) = 0.01, 0.35] higher in the group of 
daughters with prenatal PFOS concentrations 
in the upper exposure tertile compared with 
the group of daughters with prenatal PFOS 
in the lower tertile (Table 3). This result was 
similar to that of the unadjusted PFOS model. 
In addition, none of the covariates were asso-
ciated with prenatal PFOS at a chi-square 
p-value < 0.20; therefore, the parsimonious 
model is the same as the unadjusted model.
Similar patterns were observed for PFOA 
(β = 0.24; 95% CI: 0.05, 0.43) and PFHxS 
(β = 0.18; 95% CI: 0.00, 0.35), where total 
testosterone levels in fully adjusted models were 
on average higher in the group of daughters 
with prenatal exposure in the upper tertile 
compared with the group in the lower tertile 
(Table 3). The parsimonious model for PFOA, 
which was adjusted only by maternal educa-
tion, showed similar results (β = 0.18; 95% CI: 
0.01, 0.36) to those of the fully adjusted 
model. The parsimonious model for PFHxS, 
adjusted by maternal smoking during preg-
nancy, maternal age at delivery, and maternal 
prepregnancy BMI, also showed similar results 
(β = 0.20; 95% CI: 0.02, 0.38) to those of 
the fully adjusted PFHxS model. In the fully 
adjusted model, the difference in average 
total testosterone concentrations in daughters 
with prenatal PFNA concentrations in the 
upper tertile compared with daughters with 
prenatal PFNA in the lower tertile was smaller 
(β = 0.05; 95% CI: –0.14, 0.24) than those 
observed for other PFAAs. The PFNA parsimo-
nious model (β = 0.10; 95% CI: –0.08, 0.28), 
which was adjusted only for time of day when 
daughter’s blood sample was obtained, showed 
a somewhat higher average total testosterone 
in daughters with prenatal PFNA in the upper 
tertile compared with daughters with prenatal 
PFNA in the lower tertile. 
In separate regression models using 
the same adjustment approach described 
above (Table 3), we also explored asso-
ciations of total testosterone concentra-
tions in daughters with continuous prenatal 
PFAAs. In fully adjusted models, differ-
ences in total testosterone concentrations 
per nanogram per milliliter increase were 
Table 1. Distribution of PFAAs concentrations in serum from pregnant mothers and of outcomes in serum 
from daughters at 15 years of age.
Analyte n Minimum 25th Median 75th 95th Maximum
In maternal serum
PFOSa (ng/mL) 72 7.6 15.1 19.2 25.0 44.9 69.2
PFOAa (ng/mL) 72 1.1 2.7 3.6 4.7 7.6 14.6
PFHxSa (ng/mL) 72 0.2 1.2 1.6 2.1 4.6 54.1
PFNAa (ng/mL) 72 0.2 0.4 0.5 0.7 0.8 1.1
In daughters’ serum
Total testosterone (nmol/L) 72 0.2 0.7 0.8 1.1 1.3 1.7
Sex hormone-binding globulin (nmol/L) 72 7.9 37.6 52.1 72.73 110.3 135.3
25th, 75th, and 95th are percentiles.
aLimits of detection are for PFOS 0.2 ng/mL, for PFOA and PFHxS 0.1 ng/mL, and for PFNA 0.082 ng/mL.
Table 2. Frequency distribution or means ± SDs 
for study covariates.
Covariates
n (%) or 
mean ± SD
Total 72 (100.0)
Maternal covariates
Smoking during first trimester 
Yes 6 (8.3)
No 66 (91.7)
Educational level 
Lowest 10 (13.9)
Middle 18 (25.0)
Highest 44 (61.1)
Race 
White 72 (100)
Age at delivery (years) 
< 25 8 (11.1)
25–30 28 (38.9)
≥ 30 36 (50.0)
Prepregnancy body mass index (kg/m2) 22.10 ± 3.27
Daughters’ covariates
Time of blood draw 
0800–0900 hours 37 (51.4)
1200–1500 hours 35 (48.6)
Age at menarche (years) 
< 12 4 (5.5)
12–13 57 (79.2)
14 11 (15.3)
BMI (kg/m2) 21.14 ± 2.57
Menarcheal 72 (100.0)
The mean age at menarche in the study group was 
12.62 ± 0.90. 
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rather similar for PFOS (β = 0.006; 95% CI: 
0.001, 0.012), PFOA (β = 0.033; 95% CI: 
0.001, 0.066), and PFHxS (β = 0.003; 
95% CI: –0.006, 0.012), compared with 
differences in total testosterone concentrations 
per nanogram per milliliter increase in PFNA 
(β = 0.224; 95% CI: –0.089, 0.536). Overall, 
results from fully adjusted models and from 
parsimonious models were similar. After exclu-
sions of influential data points, the difference 
in total testosterone concentration per unit 
increase in fully adjusted models for PFOS 
was 0.009 (95% CI: 0.000, 0.018); PFOA 
was 0.056 (95% CI: 0.000, 0.112); PFHxS 
was 0.083 (95% CI: –0.016, 0.182); and 
PFNA was 0.281 (95% CI: –0.011, 0.671). 
Compared with results from models before 
exclusion of influential data points, regression 
coefficients were slightly larger.
In the fully adjusted models, SHBG 
concentrations were on average higher in 
daughters with prenatal PFOS (β = 3.46; 
95% CI: –12.06, 18.98), PFOA (β = 5.02; 
95% CI: –13.07, 23.11), and PFNA 
(β = 7.91; 95% CI: –8.69, 24.52) concen-
trations in the upper tertile compared with 
daughters with prenatal concentrations in the 
lower tertile (Table 4). In contrast, SHBG 
concentrations were on average lower in 
daughters with prenatal PFOS (β = –2.86; 
95% CI:  –18.80,  13.09) and PFNA 
(β = –4.53; 95% CI: –19.96, 10.90) in 
the middle tertile compared with the lower 
tertile in respective fully adjusted models. For 
PFHxS (β = –5.3; 95% CI: –21.61, 11.00), 
SHBG concentrations were on average lower 
in the group of girls with prenatal concentra-
tions in the upper tertile compared with those 
in the lower tertile. Parsimonious models 
showed rather similar results to those of their 
respective fully adjusted models.
Discussion
We explored the influence of prenatal 
exposure to PFOS, PFOA, PFHxS, and 
PFNA on testosterone and SHBG serum 
concentrations at 15 years of age in females. 
In our study of 72 ALSPAC daughters, 
prenatal exposure to PFOA, PFOS, and 
PFHxS were associated with higher total 
testosterone concentrations. To our knowl-
edge, there is only one previous published 
study where associations of prenatal PFOS 
and PFOA with total testosterone and SHBG 
concentrations were determined (Kristensen 
et al. 2013). In this study, total testosterone 
and SHBG were obtained at 20 years of 
age in a sample of 75 female users of non-
hormone contraceptives who were enrolled 
in a population-based Danish cohort with 
magnitude of exposure similar to that of 
our study group. Kristensen et al. (2013) 
constructed linear regression models using 
continuous PFOS and PFOA exposure and 
natural log–transformed study outcomes, 
adjusted by mother’s smoking and income, 
and daughter’s smoking, BMI, luteinizing 
and follicule-stimulating hormones, and 
estradiol. For total testosterone, the regres-
sion coefficient for the association with PFOS 
(β = 0.009) in the study by Kristensen et al. 
(2013) appeared to be of similar magnitude 
to that of our study, though it exhibited 
wider confidence intervals. The regression 
coefficient for the association with PFOA 
(β = –0.003) was closer to the null than 
the one in our study, and it also exhibited 
wider confidence intervals. For SHBG, the 
regression coefficients for the association with 
PFOS (β = 0.006) and PFOA (β = 0.011) 
in the study by Kristensen et al. (2013) were 
close to the null compared with those in our 
Figure 1. Scatter plots for total testosterone concentrations in 15-year-old daughters by prenatal PFOS (A), 
PFOA (B), PFHxS (C), and PFNA (D) serum concentrations with unadjusted linear regression line.
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Table 3. Regression coefficients and 95% CIs from linear regression models for serum total testosterone 
concentrations (nmol/L) in 15-year-old daughters by tertiles and continuous prenatal PFAAs.
Concentration  
(ng/mL) n Mean ± SD
Unadjusted  
β (95% CI)
Fully adjusted  
β (95% CI)a
Parsimonious  
β (95% CI)b
PFOS
≤ 15.8 24 0.76 ± 0.29 Reference Reference Reference
15.9–22.6 24 0.79 ± 0.26 0.03 (–0.14, 0.20) 0.10 (–0.07, 0.28) 0.03 (–0.14, 0.20)
> 22.6 24 0.97 ± 0.32 0.20 (0.03, 0.37) 0.18 (0.01, 0.35) 0.20 (0.03, 0.37)
Per 1 ng/mL 0.008 (0.002, 0.014) 0.006 (–0.001, 0.012) 0.008 (0.002, 0.014)
PFOA
≤ 2.9 24 0.74 ± 0.29 Reference Reference Reference
2.9–4.1 24 0.82 ± 0.32 0.07 (–0.09, 0.24) 0.15 (–0.02, 0.32) 0.10 (–0.07, 0.27)
> 4.1 24 0.96 ± 0.26 0.22 (0.05, 0.39) 0.24 (0.05, 0.43) 0.18 (0.01, 0.36)
Per 1 ng/mL 0.037 (0.006, 0.068) 0.033 (–0.001, 0.066) 0.030 (–0.002, 0.061)
PFHxS
≤ 1.2 24 0.74 ± 0.31 Reference Reference Reference
1.3–1.9 24 0.83 ± 0.28 0.10 (–0.07, 0.26) 0.18 (0.00, 0.37) 0.14 (–0.05, 0.33)
> 1.9 24 0.95 ± 0.29 0.21 (0.04, 0.38) 0.18 (0.00, 0.35) 0.20 (0.02, 0.38)
Per 1 ng/mL 0.005 (–0.003, 0.014) 0.003 (–0.006, 0.012) 0.005 (–0.004, 0.014)
PFNA
≤ 0.4 26 0.81 ± 0.34 Reference Reference Reference
0.5–0.6 25 0.84 ± 0.30 0.04 (–0.13, 0.21) 0.08 (–0.10, 0.25) 0.07 (–0.11, 0.24)
> 0.6 21 0.88 ± 0.26 0.07 (–0.11, 0.25) 0.05 (–0.14, 0.24) 0.10 (–0.08, 0.28)
Per 1 ng/mL 0.249 (–0.045, 0.543) 0.224 (–0.089, 0.536) 0.292 (–0.003, 0.586)
aEach PFAA was modeled separately and adjusted by SHBG concentration, maternal education, maternal age at 
delivery, maternal prepregnancy BMI, maternal smoking during pregnancy, time of day daughter’s blood sample was 
obtained, daughter’s age at menarche, and daughter's BMI at 15 years. bEach PFAA was modeled separately and 
adjusted only by those covariates associated with the corresponding PFAA at p < 0.20. Models were adjusted by PFOS, 
none included; PFOA, maternal education; PFHxS, maternal smoking during pregnancy, maternal age at delivery, and 
maternal prepregnancy BMI; PFNA, time of day daughter’s blood sample was obtained.
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study. Variations in covariates used in the 
adjusted regression analyses and use of natural 
log–transformed outcomes could explain the 
differences between the results of Kristensen 
et al. (2013) and our study.
Testosterone has been reported to exhibit 
both circadian and menstrual cycle variation 
(Ankarberg and Norjavaara 1999; Bui et al. 
2013). These represent sources of random error 
that could bias measures of association. We 
used time of day the daughters’ blood sample 
was drawn to explore circadian variation and 
included this variable in the multivariate 
regression analyses. We did not have informa-
tion on the time of the menstrual cycle when 
blood samples were obtained, so it remains a 
potential source of variation in our study.
Testosterone circulates in the blood-
stream mostly bound to SHBG (Davison and 
Davis 2003). SHBG was not associated with 
prenatal PFAA exposure in our study. Other 
studies did not find associations between 
SHBG and either prenatal or cross-sectional 
exposure to PFAAs in male or female adoles-
cents (Joensen et al. 2013; Kristensen et al. 
2013; Vested et al. 2013). Although PFAAs 
appear to have an affinity for SHBG binding 
sites (Jones et al. 2003), it is not known 
whether exposure to PFAAs could actually 
alter circulating SHBG concentrations.
We did not find clear evidence of an 
association of prenatal exposure to PFNA 
with circulating testosterone concentrations. 
Coefficients were close to the null for the tertile 
estimates, but the coefficients for the contin-
uous exposure were substantially larger than 
for the other PFAAs, though much less precise. 
We found that PFNA exhibited lower median 
serum concentration and narrower IQR than 
the other analytes tested. In a representative 
sample of the U.S. population, PFNA levels 
went up since the phaseout of PFOS in the 
early 2000s (Kato et al. 2011), possibly because 
it is used as a PFOS substitute. In our study, 
serum samples were collected from pregnant 
women before the phaseout of PFOS; thus 
PFNA exposure levels are low compared 
with more recent exposure levels seen in the 
United States (Kato et al. 2011) and elsewhere 
(Joensen et al. 2013).
Daughter’s BMI at 15 years and age 
at menarche were introduced in the fully 
adjusted regression models. If daughter’s BMI 
at 15 years and age at menarche are actually 
descendent of the study outcomes, their use 
as a covariate in the model is unnecessary. 
Neither daughter’s BMI at 15 years nor age 
at menarche remained in the models adjusted 
only by covariates that were associated with the 
PFAA at p < 0.20. In addition to not having an 
impact on precision, their exclusion from the 
models did not appear to meaningfully change 
the magnitude of the regression coefficients, so 
it does not affect bias.
The mode of action through which prenatal 
exposures to the PFAAs could alter testosterone 
concentrations remains to be explained, but 
may involve several pathways. One mode of 
action could involve alterations in choles-
terol metabolism through PPARα activation. 
Alterations in the expression of genes associated 
with lipid transport, lipoprotein metabolism, 
and cholesterol biosynthesis in fetal livers of 
mice prenatally exposed to PFOA, consistent 
with PPARα activation, suggest opportunities 
of fetal programming of PFOA (Rosen et al. 
2007). Another mode of action could involve 
activation of the PPARγ subtype. PPARγ is 
believed to regulate energy homeostasis and 
appears to be involved in fertility (Froment 
et al. 2006). PPARγ is expressed in adipose 
tissue, which is where conversion of about half 
of the body’s circulating testosterone occurs. 
Neither PFOS nor PFOA appears to increase 
mouse or human liver PPARγ activity in a cell 
assay study (Takacs and Abbott 2007). To 
our knowledge, it is unclear whether prenatal 
exposure to PFAA could alter adipose tissue 
PPARγ activity. Exposure to the PFAAs was 
not associated with menarche timing in our 
study population (Christensen et al. 2011), but 
it was inversely associated with birth weight 
(Maisonet et al. 2012), and birth weight could 
be regulated by PPAR activation. Last, other 
modes of action could include increased levels 
of gonadotropins (Vested et al. 2013) or 
reduced conversion to estrogens.
Associations between PFAA exposure 
and delayed menarche attainment observed 
in longitudinal and cross-sectional epidemio-
logic studies (Kristensen et al. 2013; Lopez-
Espinosa et al. 2011) and between PFAA 
exposure and increased time to pregnancy and 
irregular menstrual cycles (Fei et al. 2009) in 
cross-sectional studies suggest that alterations 
in testosterone levels may be a relevant mode 
of action. 
Our study is of an exploratory nature; 
we answered the study questions using a 
small group of enrolled cohort members 
whose exposure and outcome data had been 
collected for other purposes. Medians and 
IQRs of exposure and outcome measures in 
our study group were generally consistent 
with the distribution of these variables in their 
source samples (data not shown). Because we 
excluded girls with early menarche attainment 
from the analyses, selection bias could occur 
if prenatal PFAAs exposure influences age at 
menarche. In previous analysis, however, we 
did not find clear evidence on an association 
between prenatal PFAAs exposure and earlier 
menarche attainment (Christensen et al. 
2011). Analysis was conducted in a sample 
of females because data on prenatal exposure 
to PFAAs are not currently available for males 
enrolled in the ALSPAC cohort; nonethe-
less, the exploration of associations between 
prenatal exposures to PFAAs and hormones 
levels in males is of scientific relevance. 
Results of our study suggest a possibility 
for fetal programming by prenatal PFAA 
exposure. Besides the fetal stage, there are other 
postnatal, developmental stages when hormone 
production or signaling processes could be 
vulnerable to effects of endocrine disruptors. 
In addition, human exposure patterns to 
PFAAs are changing on a global scale as a result 
of changes in regulatory policies. To better 
understand how endocrine disruptors alter 
human reproduction, it would be valuable to 
design epidemiologic studies with the capacity 
to address multiple vulnerability periods and 
time-varying exposures.
Table 4. Regression coefficients and 95% CIs from linear regression models for serum SHBG concentra-
tions (nmol/L) in 15-year-old daughters by tertiles of prenatal PFAAs.
Concentration 
(ng/mL) n Mean ± SD
Unadjusted 
β (95% CI)
Fully adjusted  
β (95% CI)a
Parsimonious  
β (95% CI)b
PFOS
≤ 15.8 24 56.71 ± 30.42 Reference Reference Reference
15.9–22.6 24 54.31 ± 25.15 –2.40 (–18.01, 13.20) –2.86 (–18.80, 13.09) –2.40 (–18.01, 13.20)
> 22.6 24 59.29 ± 25.40 2.58 (–13.02, 18.19) 3.46 (–12.06, 18.98) 2.58 (–13.02, 18.19)
PFOA
≤ 2.9 24 55.77 ± 33.50 Reference Reference Reference
2.9–4.1 24 60.24 ± 26.07 4.47 (–11.11, 20.05) 0.32 (–15.97, 16.61) 3.83 (–11.54, 19.19)
> 4.1 24 54.30 ± 19.85 –1.47 (–17.06, 14.11) 5.02 (–13.07, 23.11) 5.45 (–10.50, 21.40)
PFHxS
≤ 1.2 24 57.87 ± 33.09 Reference Reference Reference
1.3–1.9 24 60.61 ± 24.19 2.74 (–12.76, 18.25) –2.22 (–19.62, 15.19) 0.04 (–17.17, 17.24)
> 1.9 24 51.82 ± 22.23 –6.05 (–21.55, 9.45) –5.31 (–21.61, 11.00) –6.40 (–23.01, 10.21)
PFNA
≤ 0.4 26 57.90 ± 27.50 Reference Reference Reference
0.5–0.6 25 51.75 ± 25.59 –6.15 (–21.17, 8.88) –4.53 (–19.96, 10.90) –5.15 (–20.61, 10.32)
> 0.6 21 61.34 ± 27.62 3.44 (–12.29, 19.18) 7.91 (–8.69, 24.52) 4.52 (–11.70, 20.73)
aEach PFAA was modeled separately and adjusted by maternal education, maternal age at delivery, maternal prepreg-
nancy BMI, maternal smoking during pregnancy, time of day daughter’s blood sample was obtained, daughter’s age at 
menarche, and daughter BMI at 15 years. bEach PFAA was modeled separately and adjusted only by those covariates 
associated with the corresponding PFAA at p < 0.20. Models were adjusted by PFOS, none included; PFOA, maternal 
education; PFHxS, maternal smoking during pregnancy, maternal age at delivery, and maternal prepregnancy BMI; 
PFNA, time of day daughter’s blood sample was obtained.
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